Retirement Systems of Alabama continued to hold its position in shares of Diplomat Pharmacy Inc. (NYSE:DPLO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 206,000 shares of the company’s stock at the end of the second quarter. Retirement Systems of Alabama’s holdings in Diplomat Pharmacy were worth $7,210,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. Louisiana State Employees Retirement System increased its position in shares of Diplomat Pharmacy by 2.5% in the second quarter. Louisiana State Employees Retirement System now owns 16,100 shares of the company’s stock valued at $564,000 after buying an additional 400 shares during the period. Springbok Capital Management LLC increased its position in shares of Diplomat Pharmacy by 14.8% in the first quarter. Springbok Capital Management LLC now owns 6,664 shares of the company’s stock valued at $183,000 after buying an additional 857 shares during the period. Teachers Advisors Inc. increased its position in shares of Diplomat Pharmacy by 6.1% in the first quarter. Teachers Advisors Inc. now owns 57,701 shares of the company’s stock valued at $1,581,000 after buying an additional 3,326 shares during the period. Telemus Capital LLC acquired a new position in shares of Diplomat Pharmacy during the second quarter valued at $225,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Diplomat Pharmacy by 128.6% in the second quarter. BNP Paribas Arbitrage SA now owns 11,702 shares of the company’s stock valued at $410,000 after buying an additional 6,583 shares during the period. Hedge funds and other institutional investors own 75.90% of the company’s stock.
Shares of Diplomat Pharmacy Inc. (NYSE:DPLO) traded up 1.11% during mid-day trading on Friday, reaching $28.36. 604,990 shares of the company were exchanged. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 43.63 and a beta of 1.06. Diplomat Pharmacy Inc. has a 12 month low of $22.41 and a 12 month high of $38.94. The firm’s 50-day moving average is $30.59 and its 200-day moving average is $32.06.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.02. The business earned $1.09 billion during the quarter, compared to the consensus estimate of $1.12 billion. Diplomat Pharmacy had a net margin of 1.08% and a return on equity of 11.57%. The firm’s quarterly revenue was up 34.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 EPS. On average, equities analysts forecast that Diplomat Pharmacy Inc. will post $0.94 earnings per share for the current fiscal year.
Several brokerages have weighed in on DPLO. Credit Suisse Group AG reiterated a “hold” rating and issued a $30.00 price target on shares of Diplomat Pharmacy in a report on Friday, September 16th. Zacks Investment Research downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Leerink Swann boosted their price target on Diplomat Pharmacy from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Wednesday, August 10th. Mizuho boosted their price target on Diplomat Pharmacy from $33.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, August 10th. Finally, Cowen and Company began coverage on Diplomat Pharmacy in a report on Thursday, June 23rd. They issued a “market perform” rating and a $37.00 price target for the company. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $37.50.
In related news, EVP Atheer A. Kaddis sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $30.12, for a total value of $602,400.00. Following the completion of the sale, the executive vice president now owns 20,000 shares in the company, valued at approximately $602,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Atheer A. Kaddis sold 12,325 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $35.76, for a total transaction of $440,742.00. Following the completion of the sale, the executive vice president now owns 12,325 shares of the company’s stock, valued at approximately $440,742. The disclosure for this sale can be found here. 35.40% of the stock is currently owned by corporate insiders.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.